vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and IT TECH PACKAGING, INC. (ITP). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $25.6M, roughly 1.5× IT TECH PACKAGING, INC.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -5.7%, a 2.0% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 2.1%). IT TECH PACKAGING, INC. produced more free cash flow last quarter ($1.5M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 10.5%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

IT TECH PACKAGING, INC. is a paper manufacturing enterprise primarily operating in China. It produces and distributes a diverse portfolio of paper products including corrugated packaging paper, boxboard, and printing-use cultural paper, serving sectors such as consumer goods packaging, logistics, and commercial printing across its core market.

GYRE vs ITP — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.5× larger
GYRE
$37.2M
$25.6M
ITP
Growing faster (revenue YoY)
GYRE
GYRE
+31.4% gap
GYRE
33.4%
2.1%
ITP
Higher net margin
GYRE
GYRE
2.0% more per $
GYRE
-3.7%
-5.7%
ITP
More free cash flow
ITP
ITP
$7.3M more FCF
ITP
$1.5M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
10.5%
ITP

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
GYRE
GYRE
ITP
ITP
Revenue
$37.2M
$25.6M
Net Profit
$-1.4M
$-1.4M
Gross Margin
95.3%
7.9%
Operating Margin
0.3%
-3.9%
Net Margin
-3.7%
-5.7%
Revenue YoY
33.4%
2.1%
Net Profit YoY
-340.1%
26.6%
EPS (diluted)
$-0.01
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
ITP
ITP
Q4 25
$37.2M
Q3 25
$30.6M
$25.6M
Q2 25
$26.8M
$24.8M
Q1 25
$22.1M
$10.9M
Q4 24
$27.9M
$17.6M
Q3 24
$25.5M
$25.1M
Q2 24
$25.2M
$26.2M
Q1 24
$27.2M
$6.9M
Net Profit
GYRE
GYRE
ITP
ITP
Q4 25
$-1.4M
Q3 25
$5.9M
$-1.4M
Q2 25
$1.6M
$-2.0M
Q1 25
$3.7M
$-3.5M
Q4 24
$569.0K
$-4.0M
Q3 24
$2.9M
$-2.0M
Q2 24
$4.5M
$-77.7K
Q1 24
$9.9M
$-3.7M
Gross Margin
GYRE
GYRE
ITP
ITP
Q4 25
95.3%
Q3 25
94.7%
7.9%
Q2 25
95.7%
5.1%
Q1 25
95.9%
0.8%
Q4 24
95.8%
6.3%
Q3 24
96.2%
7.6%
Q2 24
96.9%
12.4%
Q1 24
96.4%
5.8%
Operating Margin
GYRE
GYRE
ITP
ITP
Q4 25
0.3%
Q3 25
22.7%
-3.9%
Q2 25
8.1%
-7.1%
Q1 25
10.3%
-31.0%
Q4 24
2.4%
-21.5%
Q3 24
16.6%
-5.8%
Q2 24
12.7%
2.1%
Q1 24
29.7%
-51.0%
Net Margin
GYRE
GYRE
ITP
ITP
Q4 25
-3.7%
Q3 25
19.4%
-5.7%
Q2 25
5.9%
-7.9%
Q1 25
16.9%
-32.2%
Q4 24
2.0%
-22.9%
Q3 24
11.2%
-7.9%
Q2 24
18.0%
-0.3%
Q1 24
36.6%
-54.6%
EPS (diluted)
GYRE
GYRE
ITP
ITP
Q4 25
$-0.01
Q3 25
$0.03
$-0.11
Q2 25
$0.00
$-0.16
Q1 25
$0.00
$-0.35
Q4 24
$0.00
$-0.40
Q3 24
$0.01
$-0.20
Q2 24
$0.01
$-0.01
Q1 24
$0.03
$-0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
ITP
ITP
Cash + ST InvestmentsLiquidity on hand
$52.4M
Total DebtLower is stronger
$4.7M
Stockholders' EquityBook value
$106.0M
$152.0M
Total Assets
$166.1M
$175.7M
Debt / EquityLower = less leverage
0.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
ITP
ITP
Q4 25
$52.4M
Q3 25
$60.0M
Q2 25
$54.4M
Q1 25
$29.9M
Q4 24
$26.7M
Q3 24
$25.1M
Q2 24
$25.1M
Q1 24
$37.4M
Total Debt
GYRE
GYRE
ITP
ITP
Q4 25
Q3 25
$4.7M
Q2 25
$4.7M
Q1 25
$4.7M
Q4 24
$4.7M
Q3 24
$8.9M
Q2 24
$11.3M
Q1 24
$11.4M
Stockholders' Equity
GYRE
GYRE
ITP
ITP
Q4 25
$106.0M
Q3 25
$101.9M
$152.0M
Q2 25
$92.0M
$152.3M
Q1 25
$68.1M
$152.8M
Q4 24
$63.3M
$156.1M
Q3 24
$63.2M
$164.3M
Q2 24
$60.4M
$163.5M
Q1 24
$56.6M
$164.3M
Total Assets
GYRE
GYRE
ITP
ITP
Q4 25
$166.1M
Q3 25
$159.4M
$175.7M
Q2 25
$152.6M
$175.2M
Q1 25
$129.8M
$175.2M
Q4 24
$125.4M
$177.5M
Q3 24
$125.2M
$190.0M
Q2 24
$120.9M
$191.4M
Q1 24
$122.0M
$177.5M
Debt / Equity
GYRE
GYRE
ITP
ITP
Q4 25
Q3 25
0.03×
Q2 25
0.03×
Q1 25
0.03×
Q4 24
0.03×
Q3 24
0.05×
Q2 24
0.07×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
ITP
ITP
Operating Cash FlowLast quarter
$-5.6M
$1.5M
Free Cash FlowOCF − Capex
$-5.8M
$1.5M
FCF MarginFCF / Revenue
-15.5%
5.9%
Capex IntensityCapex / Revenue
0.4%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K
$3.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
ITP
ITP
Q4 25
$-5.6M
Q3 25
$4.7M
$1.5M
Q2 25
$2.1M
$1.4M
Q1 25
$-129.0K
$-2.5M
Q4 24
$-2.8M
$3.5M
Q3 24
$1.7M
$1.5M
Q2 24
$-5.5M
$721.9K
Q1 24
$2.9M
$624.4K
Free Cash Flow
GYRE
GYRE
ITP
ITP
Q4 25
$-5.8M
Q3 25
$4.0M
$1.5M
Q2 25
$1.8M
$1.3M
Q1 25
$-251.0K
$-2.5M
Q4 24
$-2.8M
$3.5M
Q3 24
$1.0M
$1.2M
Q2 24
$-6.9M
$668.3K
Q1 24
$2.7M
$615.4K
FCF Margin
GYRE
GYRE
ITP
ITP
Q4 25
-15.5%
Q3 25
13.1%
5.9%
Q2 25
6.8%
5.4%
Q1 25
-1.1%
-22.8%
Q4 24
-10.1%
19.6%
Q3 24
4.1%
4.9%
Q2 24
-27.5%
2.5%
Q1 24
9.8%
9.0%
Capex Intensity
GYRE
GYRE
ITP
ITP
Q4 25
0.4%
Q3 25
2.2%
0.0%
Q2 25
1.0%
0.1%
Q1 25
0.6%
0.1%
Q4 24
0.2%
0.1%
Q3 24
2.7%
1.0%
Q2 24
5.8%
0.2%
Q1 24
0.9%
0.1%
Cash Conversion
GYRE
GYRE
ITP
ITP
Q4 25
Q3 25
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons